GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CuraScientific Corp (OTCPK:CSTF) » Definitions » Capex-to-Operating-Cash-Flow

CuraScientific (CuraScientific) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is CuraScientific Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

CuraScientific's Capital Expenditure for the three months ended in Sep. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2023 was $-0.26 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


CuraScientific Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for CuraScientific's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CuraScientific Capex-to-Operating-Cash-Flow Chart

CuraScientific Annual Data
Trend Dec20 Dec21 Dec22
Capex-to-Operating-Cash-Flow
- - -

CuraScientific Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CuraScientific's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, CuraScientific's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CuraScientific's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CuraScientific's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CuraScientific's Capex-to-Operating-Cash-Flow falls into.



CuraScientific Capex-to-Operating-Cash-Flow Calculation

CuraScientific's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.015) / -0.254
=N/A

CuraScientific's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.255
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CuraScientific  (OTCPK:CSTF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


CuraScientific Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CuraScientific's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CuraScientific (CuraScientific) Business Description

Traded in Other Exchanges
N/A
Address
51544 Cesar Chavez Street, Suite No. 1J, Coachella, CA, USA, 92236
CuraScientific Corp manufactures commercial chemicals with a variety of commercial sterilization applications for agriculture, warehousing, hospitality, and medical facilities. The company's product, DiOx+, is a disinfectant sterilizer that kills harmful pathogens without exposing people or the environment to dangerous toxins.
Executives
Paul Quentin Goyette director 2205 LOCH WAY, EL DORADO HILLS CA 95762
William Joseph Reed director, officer: Chief Executive Officer 333 N UNIVERSITY AVE., #33, REDLANDS CA 92374
Johann Loewen director C/O METHES ENERGIES INTERNATIONAL LTD, 3651 LINDELL ROAD, SUITE D-272, LAS VEGAS NV 89103
Edouard Maurice Beaudette director 13480 N BLOOMFIELD ROAD, NEVADA CITY CA 95959
Justin Michael Gonzalez director, officer: Chief Executive Officer 15723 LAKE VERA PURDON RD., NEVADA CITY CA 95959
Eric Jason Watson director, officer: Chief Operating Officer 19553 BOWERS DRIVE, TOPANGA CA 90290

CuraScientific (CuraScientific) Headlines

From GuruFocus

Introducing Leaf of Faith

By Marketwired Marketwired 03-26-2019